Record Details

GALNS Mutations in Indian Patients With Mucopolysaccharidosis IVA
IR @ Centre for DNA Fingerprinting and Diagnostics
Title
GALNS Mutations in Indian Patients With Mucopolysaccharidosis IVA
Creator
Bidchol, A.M. Dalal, Ashwin Shah, H. Suryanarayana, S. Nampoothiri, S. Kabra, M. Gupta, N. Danda, S. Gowrishankar, K. Phadke, S.R. Kapoor, S. Kamate, M. Verma, I.C. Puri, R.D. Sankar, V.H. Radha Rama Devi, A. Patil, S.J. Ranganath, P. Jain, S.J.M.N. Agarwal, Meenal Singh, Ankur Mishra, P. Tamhankar, P.M. Gopinath, P.M. Nagarajaram, H.A. Satyamoorthy, K. Girisha, K.M.
Description
Mucopolysaccharidosis IV A (Morquio syndrome A, MPS IVA) is a lysosomal storage disease caused by the deficiency of N-acetylgalactosamine-6-sulfatase (GALNS). The mutation spectrum in this condition is yet to be determined in Indians. We aimed to analyze the mutations in the GALNS gene in Asian Indians with MPS IVA. All the exons and the adjacent intronic regions of the gene were amplified and sequenced in sixty-eight unrelated Indian families. We identified 136 mutant alleles comprising of 40 different mutations. We report twenty-two novel mutations that comprise of seventeen missense (p.Asn32Thr, p.Leu36Arg, p.Pro52Leu, p.Pro77Ser, p.Cys79Arg, p.His142Pro, p.Tyr191Asp, p.Asn204Thr, p.Gly188Ser, p.Phe216Ser, p.Trp230Cys, p.Ala291Ser, p.Gly317Arg, p.His329Pro, p.Arg386Ser, p.Glu450Gly, p.Cys501Ser), three splice-site variants (c.120+1G>C, c.1003-3C>G, c.1139+1G>A), one nonsense mutation (p.Gln414*) and one frameshift mutation (p.Pro420Leufs*440). Eighteen mutations have been reported earlier. Among these p.Ser287Leu (8.82%), p.Phe216Ser (7.35%), p.Asn32Thr (6.61%) and p.Ala291Ser (5.88%) were the most frequent mutations in Indian patients but were rare in the mutational profiles reported in other populations. These results indicate that the Indian patients may have a distinct mutation spectrum compared to those of other populations. Mutant alleles in exon 1, 7 and 8 accounted for 44.8% of the mutations, and sequencing of these exons initially may be a cost-effective approach in Asian Indian patients. This is the largest study on molecular analysis of patients with MPS IVA reported in the literature, and the first report from India. (c) 2014 Wiley Periodicals, Inc.
Publisher
John Wiley
Date
2014-11
Type
Article PeerReviewed
Language